Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Eluminex Acquires Synthetic Cornea Product in $108 Million Agreement

publication date: Jul 19, 2021

Eluminex Biosciences (Suzhou), an ophthalmology biotech, in-licensed global rights to a biosynthetic cornea developed by FibroGen. The synthetic cornea, which is intended to treat corneal blindness, is derived from recombinant human collagen Type III. Eluminex will make an $8 million upfront payment and will pay up to $64 million in milestones for the biosynthetic cornea program and $36 million in commercial milestones for the next non-corneal collagen III product. More details....

Stock Symbol: (NSDQ: FGEN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.